# A Drug Utilization Study of Radium-223 in Sweden

> **NCT02331303** · — · COMPLETED · sponsor: **Bayer** · enrollment: 37 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **OTHER:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT02331303
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2017-12-19
- **Final completion:** 2017-12-19
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02331303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02331303, "A Drug Utilization Study of Radium-223 in Sweden". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02331303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*